Development of a physiomimetic model of acute respiratory distress syndrome by using ECM hydrogels and organ-on-a-chip devices
Acute Respiratory Distress Syndrome is one of the more common fatal complications in COVID-19, characterized by a highly aberrant inflammatory response. Pre-clinical models to study the effect of cell therapy and anti-inflammatory treatments have not comprehensively reproduced the disease due to its high complexity. This work presents a novel physiomimetic in vitro model for Acute Respiratory Distress Syndrome using lung extracellular matrix-derived hydrogels and organ-on-a-chip devices. Monolayres of primary alveolar epithelial cells were cultured on top of decellullarized lung hydrogels containing primary lung mesenchymal stromal cells. Then, cyclic stretch was applied to mimic breathing, and an inflammatory response was induced by using a bacteriotoxin hit. Having simulated the inflamed breathing lung environment, we assessed the effect of an anti-inflammatory drug (i.e., dexamethasone) by studying the secretion of the most relevant inflammatory cytokines. To better identify key players in our model, the impact of the individual factors (cyclic stretch, decellularized lung hydrogel scaffold, and the presence of mesenchymal stromal cells) was studied separately. Results showed that developed model presented a more reduced inflammatory response than traditional models, which is in line with what is expected from the response commonly observed in patients. Further, from the individual analysis of the different stimuli, it was observed that the use of extracellular matrix hydrogels obtained from decellularized lungs had the most significant impact on the change of the inflammatory response. The developed model then opens the door for further in vitro studies with a better-adjusted response to the inflammatory hit and more robust results in the test of different drugs or cell therapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in Pharmacology - 13(2022) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Esther Marhuenda [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
ARDS |
|---|
| doi: |
10.3389/fphar.2022.945134 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ078848253 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ078848253 | ||
| 003 | DE-627 | ||
| 005 | 20230307011712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230307s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2022.945134 |2 doi | |
| 035 | |a (DE-627)DOAJ078848253 | ||
| 035 | |a (DE-599)DOAJfada4b93ac8b441286b7787de3dd6395 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Esther Marhuenda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of a physiomimetic model of acute respiratory distress syndrome by using ECM hydrogels and organ-on-a-chip devices |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Acute Respiratory Distress Syndrome is one of the more common fatal complications in COVID-19, characterized by a highly aberrant inflammatory response. Pre-clinical models to study the effect of cell therapy and anti-inflammatory treatments have not comprehensively reproduced the disease due to its high complexity. This work presents a novel physiomimetic in vitro model for Acute Respiratory Distress Syndrome using lung extracellular matrix-derived hydrogels and organ-on-a-chip devices. Monolayres of primary alveolar epithelial cells were cultured on top of decellullarized lung hydrogels containing primary lung mesenchymal stromal cells. Then, cyclic stretch was applied to mimic breathing, and an inflammatory response was induced by using a bacteriotoxin hit. Having simulated the inflamed breathing lung environment, we assessed the effect of an anti-inflammatory drug (i.e., dexamethasone) by studying the secretion of the most relevant inflammatory cytokines. To better identify key players in our model, the impact of the individual factors (cyclic stretch, decellularized lung hydrogel scaffold, and the presence of mesenchymal stromal cells) was studied separately. Results showed that developed model presented a more reduced inflammatory response than traditional models, which is in line with what is expected from the response commonly observed in patients. Further, from the individual analysis of the different stimuli, it was observed that the use of extracellular matrix hydrogels obtained from decellularized lungs had the most significant impact on the change of the inflammatory response. The developed model then opens the door for further in vitro studies with a better-adjusted response to the inflammatory hit and more robust results in the test of different drugs or cell therapy. | ||
| 650 | 4 | |a ARDS | |
| 650 | 4 | |a lung-on-a-chip | |
| 650 | 4 | |a extracellular matrix | |
| 650 | 4 | |a hydrogels | |
| 650 | 4 | |a mesenchymal stromal cells | |
| 650 | 4 | |a alveolar epithelial cells | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Esther Marhuenda |e verfasserin |4 aut | |
| 700 | 0 | |a Alvaro Villarino |e verfasserin |4 aut | |
| 700 | 0 | |a Maria Narciso |e verfasserin |4 aut | |
| 700 | 0 | |a Maria Narciso |e verfasserin |4 aut | |
| 700 | 0 | |a Linda Elowsson |e verfasserin |4 aut | |
| 700 | 0 | |a Isaac Almendros |e verfasserin |4 aut | |
| 700 | 0 | |a Isaac Almendros |e verfasserin |4 aut | |
| 700 | 0 | |a Isaac Almendros |e verfasserin |4 aut | |
| 700 | 0 | |a Gunilla Westergren-Thorsson |e verfasserin |4 aut | |
| 700 | 0 | |a Ramon Farré |e verfasserin |4 aut | |
| 700 | 0 | |a Ramon Farré |e verfasserin |4 aut | |
| 700 | 0 | |a Ramon Farré |e verfasserin |4 aut | |
| 700 | 0 | |a Núria Gavara |e verfasserin |4 aut | |
| 700 | 0 | |a Núria Gavara |e verfasserin |4 aut | |
| 700 | 0 | |a Núria Gavara |e verfasserin |4 aut | |
| 700 | 0 | |a Jorge Otero |e verfasserin |4 aut | |
| 700 | 0 | |a Jorge Otero |e verfasserin |4 aut | |
| 700 | 0 | |a Jorge Otero |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Pharmacology |d Frontiers Media S.A., 2010 |g 13(2022) |w (DE-627)DOAJ000099732 |x 16639812 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fphar.2022.945134 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/fada4b93ac8b441286b7787de3dd6395 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fphar.2022.945134/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1663-9812 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 | ||